行動基因香港與癌症資訊網合作 推廣癌症患者的精準醫療

Sep 11^th, 2024 香港–行動基因香港ACT Genomics (Hong Kong) Limited (行動基因)與癌症資訊網Cancerinformation正式簽署合作協議(MoU)，旨在促進癌症患者對癌症及精準醫療的認識，並提高相關檢測的重要性。此項合作雙方共同致力於推動患者教育及增進精準醫療可近性的目標。

行動基因集團的執行長Walt Ling表示：「行動基因致力於為患者提供快速、穩定、高品質的精準醫療檢測。我們與癌症資訊網的合作，將不僅增進癌症患者對精準醫療的認識，還將促進基因檢測的可及性和普及性。我們非常重視患者教育，透過這次合作，我們將推出一系列的宣導活動和資源，幫助患者更清楚地了解他們的治療選擇和如何利用最新的醫療科技來改善他們的治療效果。我們相信，只有通過知識的傳遞，才能真正賦予患者權力，讓他們能夠做出最有利於自身健康的決策。」

癌症資訊網慈善基金主席方嘉儀（Natalie Fong）亦表示說：「我們非常高興能與行動基因香港攜手合作。這次合作不僅在於提供精準醫療的技術支援，更重要的是通過教育和宣導，讓患者及其家屬深入了解癌症治療的最新發展和選擇。我們希望通過這些教育活動，能夠提供患者更多的選擇、更廣闊的視野和重要的支援。我們的目標是幫助患者更全面地了解他們的病情和治療選擇，並提供有力的支持，幫助他們在抗癌的路上走得更遠。」

此次合作預計將顯著提升癌症患者和大眾對精準醫療及其相關檢測的重要性的了解，促進對癌症治療選擇的知識普及。透過行動基因香港提供的特別折價計劃，患者接受精準醫療的門檻將大幅降低，從而促進更多患者進行早期基因篩檢和診斷，實現早期治療，提升存活率和生活品質。此外，這一合作亦能幫助醫生更精準地為患者制定個性化治療方案，增強治療效果。雙方透過教育和資源共享，將進一步增強患者在治療決策過程中的主動性和參與度，使他們能夠更有信心地面對癌症治療過程。

行動基因香港和癌症資訊網將攜手合作，為癌症患者及其家庭帶來更多的希望和支持。這一合作不僅僅是兩個機構之間的協議，更是對所有癌症患者及其家庭的一種承諾，旨在通過先進的醫療技術和教育活動，幫助他們戰勝癌症，迎接更光明的未來。

ACT Genomics (Hong Kong) Limited Partners with Cancerinformation to Promote Precision Medicine for Cancer Patients

Sep 11^th, 2024 Hong Kong – ACT Genomics (Hong Kong) Limited (“ACTG”) and Cancerinformation have officially signed a Memorandum of Understanding (MoU) to enhance cancer patients’ understanding of cancer and precision medicine and to emphasize the importance of related testing. This collaboration is dedicated to advancing patient education and increasing the accessibility of precision medicine.

Walt Ling, CEO of ACTG Group stated, “ACTG is committed to providing fast, reliable, and high-quality precision medical testing for patients. Our collaboration with Cancerinformation will not only enhance cancer patients’ awareness of precision medicine but also promote the accessibility and widespread use of genetic testing. We place a strong emphasis on patient education, and through this collaboration, we will launch a series of outreach activities and resources to help patients better understand their treatment options and how to utilize the latest medical technology to improve their outcomes. We believe that only through the transfer of knowledge can we truly empower patients, enabling them to make the most beneficial decisions for their health.”

Natalie Fong, Chairperson of the Cancerinformation Charity Foundation, added, “We are very pleased to partner with ACT Genomics (Hong Kong) Limited. This collaboration is not only about providing technical support for precision medicine but, more importantly, about educating and informing patients and their families about the latest developments and options in cancer treatment. Through these educational activities, we hope to offer patients more choices, broader perspectives, and essential support. Our goal is to help patients better understand their conditions and treatment options, providing them with the necessary support to move further along their journey against cancer.”

This partnership is expected to significantly enhance the understanding of the importance of precision medicine and related testing among cancer patients and the general public, promoting the dissemination of knowledge about cancer treatment options. Through the special discount program offered by ACTG, the barrier to accessing precision medicine will be substantially lowered, encouraging more patients to undergo early genetic screening and diagnosis, thereby achieving early treatment and improving survival rates and quality of life. Moreover, this collaboration will help doctors provide more accurate and personalized treatment plans for patients, enhancing treatment outcomes. Through shared education and resources, both parties will further empower patients to take an active role in their treatment decision-making process, giving them more confidence in facing the cancer treatment journey.

ACTG and Cancerinformation will work together to bring more hope and support to cancer patients and their families. This partnership is not just an agreement between two organizations; it is a commitment to all cancer patients and their families, aiming to help them overcome cancer and embrace a brighter future through advanced medical technology and educational activities.